Cantor Fitzgerald Issues Negative Estimate for CVRx Earnings

CVRx, Inc. (NASDAQ:CVRX) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for CVRx in a report issued on Tuesday, May 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.97) per share for the year, down from their previous forecast of ($1.90). The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.03. CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. The firm had revenue of $12.35 million for the quarter, compared to analyst estimates of $14.68 million.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group lowered their price target on shares of CVRx from $23.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, April 8th. JPMorgan Chase & Co. restated an “underweight” rating and set a $7.00 target price (down from $15.00) on shares of CVRx in a research note on Friday, May 9th. Piper Sandler dropped their target price on CVRx from $20.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Lake Street Capital reduced their price target on CVRx from $19.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, April 8th. Finally, Craig Hallum lifted their price objective on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.50.

CVRx Trading Up 17.0%

NASDAQ CVRX opened at $6.19 on Thursday. The company’s fifty day simple moving average is $8.79 and its 200-day simple moving average is $12.46. CVRx has a 52 week low of $4.30 and a 52 week high of $18.55. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The stock has a market cap of $161.39 million, a P/E ratio of -2.30 and a beta of 1.39.

Hedge Funds Weigh In On CVRx

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC acquired a new stake in shares of CVRx during the first quarter worth $28,000. Tower Research Capital LLC TRC raised its stake in CVRx by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company’s stock worth $49,000 after acquiring an additional 1,186 shares during the period. GAMMA Investing LLC lifted its holdings in CVRx by 1,469.3% in the first quarter. GAMMA Investing LLC now owns 4,598 shares of the company’s stock worth $56,000 after acquiring an additional 4,305 shares during the last quarter. Quarry LP acquired a new position in CVRx in the fourth quarter valued at approximately $69,000. Finally, Whittier Trust Co. bought a new position in shares of CVRx during the first quarter valued at approximately $73,000. 75.27% of the stock is currently owned by institutional investors.

Insider Activity at CVRx

In other news, Director Kirk G. Nielsen bought 61,200 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The stock was bought at an average price of $5.23 per share, for a total transaction of $320,076.00. Following the transaction, the director now owns 1,899,168 shares in the company, valued at $9,932,648.64. The trade was a 3.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders bought a total of 67,700 shares of company stock valued at $351,266 over the last three months. 13.90% of the stock is owned by insiders.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.